Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus Season
- Ethan Litman; Tina Yi Jin Hsieh; Anna Modest; Kathleen Clarke; Melissa Dzinoreva; Valerie Perrinez
Access Resources
About
This research letter looks at a study that analyzed the uptake of RSVpreF vaccination during pregnancy and nirsevimab administration to infants during the 2023 to 2024 RSV season. Results showed 20.5% of mothers and 35.0% of infants received RSV immunizations, with higher rates in pharmacy- and office-administered immunizations during hospitalization. Maternal vaccination disparities were observed, while infant vaccination rates were consistent.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.